Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case
Samuel J. Klempner, Andrew Hendifar, Kevin Waters, Nicholas N. Nissen, Eric Vail, Richard Tuli, Alain C. Mita
Topics & Concepts
PembrolizumabTemozolomideSomatic hypermutationRefractory (planetary science)NeoplasmMedicineCancer researchInternal medicineOncologyGlioblastomaBiologyAntibodyCancerPathologyImmunologyAstrobiologyImmunotherapyB cellNeuroendocrine Tumor Research AdvancesLung Cancer Research StudiesNeuroblastoma Research and Treatments